Clinical Trial Update: A Study of Tocilizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARDs [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating tocilizumab in rheumatoid arthritis patients who had an inadequate response to non-biologic DMARDs has completed, with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2016-03-31